Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Stay Informed: Medical and Research Updates
Connect With Us! Visit the Children's Corner for Macular Degeneration
 

 

BrightFocus-supported Researchers Identify a New Therapeutic Target for Dry AMD

August 9, 2012

Findings: Advanced forms of dry age-related macular degeneration (AMD), called geographic atrophy, can lead to severe vision loss or blindness. Currently, there are no effective treatments for dry AMD (unlike wet AMD, which has several treatment options).

Over a tenth of the human genome is “junk” DNA that makes a product called Alu RNA. In healthy people, a protein called Dicer1 chops up these Alu RNAs. This research team found that people with this advanced form of dry AMD have lower levels of Dicer1 in particular retina cells called retinal pigment epithelium (RPE). There is a buildup of the Alu RNA that then kills these cells, leading to blindness. A team of researchers, including BrightFocus-funded Dr. Judit Baffi, has identified that the Alu RNA buildup triggers the activation of another protein that then leads to RPE cell death. The scientists prevented this protein, called ERK1/2, from killing the RPE cells in mice by using a compound that specifically blocked its activation.

Significance:
This research is the continuation of pivotal BrightFocus-funded discoveries that were published in 2011 and in early 2012 (see links to those descriptions below). In this latest breakthrough, the team identified that ERK1/2 protein is the “contract killer” of RPE cells in mice, “hired” by the buildup of Alu RNA. If further testing is successful, in the future, drugs could be designed to target ERK1/2 as a treatment option for this blinding form of dry AMD.

BrightFocus funded Dr. Judit Baffi, was a pivotal member of this research team. Senior author on this paper, Dr. Jayakrishna Ambati (http://www.brightfocus.org/research/grants/migrated/adenoassociated-viral-gene-therapy-in.html) and (http://www.brightfocus.org/research/grants/migrated/the-role-of-sparc-in-macular-propensit.html) is a former BrightFocus grantee.

View all news updates for macular degeneration


Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.

Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.

Twitter YouTube Facebook Shop for a Cause Pinterest Google+ Connect With Us